Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Shin, Seok Joon ^a   Chung, Sungjin ^a   Kim, Soo Jung ^a   Lee, Eun Mi ^a   Yoo, Young Hye ^a   Kim, Ji Won ^a   Ahn, Yu Bae ^a   Kim, Eun Sook ^a   Moon, Sung Dae ^a   Kim, Myung Jun ^a   Ko, Seung Hyun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CATALASE; COLLAGEN TYPE 4; COPPER ZINC SUPEROXIDE DISMUTASE; DAPAGLIFLOZIN; HEMOGLOBIN A1C; MANGANESE SUPEROXIDE DISMUTASE; RAS PROTEIN; RENIN; SODIUM GLUCOSE COTRANSPORTER 2; VOGLIBOSE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ALDOSTERONE; BENZHYDRYL DERIVATIVE; CHYMOSIN; GLUCOSIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HORMONE URINE LEVEL; INFLAMMATORY CELL; LIPID PEROXIDATION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; HYPERGLYCEMIA; KIDNEY; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOLOGY;

ALDOSTERONE; ANIMALS; BENZHYDRYL COMPOUNDS; CHYMOSIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GLUCOSIDES; HYPERGLYCEMIA; KIDNEY; LIPID PEROXIDATION; MALE; RATS, INBRED OLETF; RENIN-ANGIOTENSIN SYSTEM; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84993929544     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165703     Document Type: Article

References (49)

1. Park CW. Diabetic Kidney Disease: From epidemiology to clinical perspectives. Diabetes Metab J. 2014; 38(4):252-60. doi: 10.4093/dmj.2014.38.4.252 PMID: 25215271
2. Zhao F, Zhang L, Lu J., Guo K, Wu M, Yu H., et al. The Chronic Kidney Disease Epidemiology Collaboration equation improves the detection of hyperfiltration in Chinese diabetic patients. Int J Clin Exp Med. 2015; 8(12):22084-97. PMID: 26885183
3. Satirapoj B, Adler SG Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract. 2014; 33(3):121-31. doi: 10.1016/j.krcp.2014.08.001 PMID: 26894033
4. Gregg EW, Li Y, Wang J., Burrows NR, Ali MK, Rolka D, et al Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014; 370(16):1514-23. doi: 10.1056/NEJMoa1310799 PMID: 24738668
5. Anderson S, Jung FF, Ingelfinger JR Renal renin-angiotensin system in diabetes: functional, immuno-histochemical, and molecular biological correlations. Am J Physiol. 1993; 265(4 Pt 2):F477-86.
6. Barutta F, Bruno G, Grimaldi S., Gruden G. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 2015; 48(3):730-42. doi: 10.1007/s12020-014-0437-1 PMID: 25273317
7. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006; 86(3):747-803 doi: 10.1152/physrev.00036.2005 PMID: 16816138
8. Jones ES, Vinh A, McCarthy C.A., Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008; 120(3):292-316. doi: 10.1016/j.pharmthera.2008.08.009 PMID: 18804122
9. Barber MN, Sampey DB, Widdop RE AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999; 34(5):1112-6. PMID: 10567191
10. Shin SJ, Lim JH, Chung S, Youn D.Y., Chung HW, Kim HW, et al. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res. 2009; 32(10):835-45. doi: 10.1038/hr.2009.107 PMID: 19644507
11. Gurley SB, Coffman TM The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007; 27(2):144-52. doi: 10.1016/j.semnephrol.2007.01.009 PMID: 17418683
12. Durvasula RV, Shankland SJ Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol. 2008; 294(4):F830-9. doi: 10.1152/ajprenal.00266.2007 PMID: 18216149
13. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, et al. Attenuating effect of angio-tensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol. 2011; 300(6):F1271-82. doi: 10.1152/ajprenal.00065.2010 PMID: 21367916
14. Feliers D, Kasinath BS Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells. Mol Cell Endocrinol. 2010; 314(1):136-42. doi: 10.1016/j.mce.2009.09.009 PMID: 19765632
15. Fan YY, Kobori H, Nakano D., Hitomi H, Mori H, Masaki T, et al. Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats. Horm Metab Res. 2013; 45 (5):338-43. doi: 10.1055/s-0032-1331256 PMID: 23322513
16. Chao EC, Henry RR SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9(7):551-9. doi: 10.1038/nrd3180 PMID: 20508640
17. Jung CH, Jang JE, Park JY A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014; 38(4):261-73. doi: 10.4093/dmj.2014.38.4.261 PMID: 25215272
18. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013; 29(5):347-56. doi: 10.1002/dmrr.2403 PMID: 23463735
19. Bouchie A. SGLT2 inhibitors enter crowded diabetes space. Nat Biotechnol. 2013; 31(6):469-70. doi: 10.1038/nbt0613-469 PMID: 23752410
20. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012; 72(17):2289-312. doi: 10.2165/11209910-000000000-00000 PMID: 23170914
21. DeFronzo RA, Hompesch M, Kasichayanula S., Liu X, Hong Y, Pfister M., et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36(10):3169-76. doi: 10.2337/dc13-0387 PMID: 23735727
22. Zaccardi F, Webb DR, Htike Z.Z., Youssef D., Khunti K, Davies MJ. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab. 2016 Apr 5. [Epub ahead of print]
23. Fujimori Y, Katsuno K, Nakashima I., Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabo-nate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008; 327(1):268-76. doi: 1124/jpet.108.140210 PMID: 18583547
24. Macdonald FR, Peel JE, Jones H.B., Mayers RM, Westgate L, Whaley JM, et al The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010; 12(11):1004-12. doi: 10.1111/j.1463-1326.2010.01291.x PMID: 20880347
25. Chen L, Klein T, Leung PS Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012; 12(8):995-1004. PMID: 22804249
26. Mori Y, Kitahara Y, Miura K., Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine. 2004; 23(1):39-43. doi: 10.1385/ENDO:23:1:39 PMID: 15034195
27. Goto Y, Yamada K, Ohyama T., Matsuo T, Odaka H, Ikeda H. An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Diabetes Res Clin Pract. 1995; 28(2):81-7. PMID: 7587923
28. Nozako M, Koyama T, Nagano C., Sato M, Matsumoto S, Mitani K., et al. An Atherogenic Paigen-Diet Aggravates Nephropathy in Type 2 Diabetic OLETF Rats. PLOS ONE. 2015; 10(11):e0143979. doi: 10.1371/journal.pone.0143979 PMID: 26606054
29. Kawano K, Hirashima T, Mori S., Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992; 41:1422-8. PMID: 1397718
30. Park CW, Kim HW, Ko S.H., Chung HW, Lim SW, Yang CW, et al Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55(4):885-93. PMID: 16567507
31. Weibel ER. Practical methods for biological morphometry. Stereological Methods. London: Academic Press, 1979; 44-45
32. Kim J, Kil IS, Seok Y.M., Yang ES, Kim DK, Lim DG, et al Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem. 2006; 281(29):20349-56. doi: 10.1074/jbc.M512740200 PMID: 16682413
33. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int. 2005; 67(6):2221-38. doi: 10.1111/j.1523-1755.2005.00327.x PMID: 15882265
34. Wolf G. Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant. 1999; 14 Suppl 1:42-4.
35. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol. 2009; 5 (2):89-100. doi: 10.1038/ncpneph1015 PMID: 19065132
36. Abdo S, Zhang SL, Chan JS Reactive Oxygen Species and Nuclear Factor Erythroid 2-Related Factor 2 Activation in Diabetic Nephropathy: A Hidden Target. J Diabetes Metab. 2015; 6(6).
37. Tervaert TW, Mooyaart AL, Amann K, Cohen A.H., Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21:556-63. doi: 10.1681/ASN.2010010010 PMID: 20167701
38. Singh R, Alavi N, Singh A.K., Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesan-gial matrix degradation. Diabetes. 1999; 48(10):2066-73 PMID: 10512375
39. Zhang SL, Tang SS, Chen X, Filep J.G., Ingelfinger JR, Chan JS. High levels of glucose stimulate angio-tensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology. 2000; 141(12):4637-46. doi: 10.1210/endo.141.12.7844 PMID: 11108278
40. Hsieh TJ, Fustier P, Zhang S.L., Filep JG, Tang SS, Ingelfinger JR, et al High glucose stimulates angio-tensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology. 2003; 144(10):4338-49 doi: 10.1210/en.2003-0220 PMID: 12960040
41. Kreisberg JI, Radnik RA, Kreisberg SH Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF beta or PMA. Kidney Int. 1996; 50 (3):805-10. PMID: 8872954
42. Wu J, Jiang Q, Chen X., Wu XH, Chan JS. Identification of a novel mouse hepatic 52 kDa protein that interacts with the cAMP response element of the rat angiotensinogen gene. Biochem J. 1998; 329(Pt 3):623-9.
43. Visavadiya NP, Li Y, Wang S. High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB. Nephron Exp Nephrol. 2011; 117(3):e62-70. doi: 10.1159/000320594 PMID: 20814220
44. Shah NK, Deeb WE, Choksi R, Epstein BJ Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012; 32(1):80-94. doi: 10. 1002/PHAR.1010 PMID: 22392830
45. Paisley AN, Yadav R, Younis N., Rao-Balakrishna P, Soran H. Dapagliflozin: a review on efficacy, clinical effectiveness and safety. Expert Opin Investig Drugs. 2013; 22(1):131-40. doi: 10.1517/13543784.2013.740009 PMID: 23127205
46. Komala MG, Panchapakesan U, Pollock C., Mather A. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2013; 22(1):113-9. doi: 10.1097/MNH.0b013e32835a17ae PMID: 23042029
47. Terami N, Ogawa D, Tachibana H., Hatanaka T, Wada J, Nakatsuka A., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLOS ONE. 2014; 24; 9(6):e100777. doi: 10.1371/journal.pone.0100777 PMID: 24960177
48. Nagata T, Fukuzawa T, Takeda M., Fukazawa M, Mori T, Nihei T et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 2013; 170:519-31. doi: 10.1111/bph.12269 PMID: 23751087
49. Tahara A, Kurosaki E, Yokono M., Yamajuku D, Kihara R, Hayashizaki Y., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013; 715(1-3):246-55 doi: 10.1016/j.ejphar.2013.05.014 PMID: 23707905